Veracyte, Inc.: New Data Suggest Veracyte's Envisia Genomic Classifier Can Help Predict Disease Progression in Interstitial Lung Disease Patients Treated with Combination Immunosuppressive Therapy

Findings presented at the European Respiratory Society International Congress 2022 Veracyte, Inc. (Nasdaq: VCYT) today announced new data suggesting that the Envisia Genomic Classifier (EGC) can

Related Keywords

London ,City Of ,United Kingdom ,California ,United States ,South San Francisco ,Brompton ,Medway ,Tracy Morris ,Shayla Gorman ,Twitter ,European Respiratory Society International Congress ,Nasdaq ,Research Use ,International Congress ,European Respiratory Society ,Global Corporate Communications ,Veracyte Inc ,Envisia Genomic Classifier ,Athol Wells ,Royal Brompton Hospital ,Bill Bulman ,Counter Analysis System ,Note Regarding Forward Looking Statements ,Annual Report ,Quarterly Report ,Nanostring Technologies ,Decipher Prostate Genomic Classifier ,Research Use Only ,Investor Relations ,Veracyte ,Data ,Uggest ,Envisia ,Enomic ,Classifier ,Help ,Redict ,Disease ,Progression ,Interstitial ,Young ,Patients ,Reated ,Combination ,Immunosuppressive ,Therapy ,